Alaunos Therapeutics Statistics
Total Valuation
TCRT has a market cap or net worth of $5.04 million. The enterprise value is $4.68 million.
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRT has 2.42 million shares outstanding. The number of shares has increased by 27.10% in one year.
| Current Share Class | 2.42M |
| Shares Outstanding | 2.42M |
| Shares Change (YoY) | +27.10% |
| Shares Change (QoQ) | -16.23% |
| Owned by Insiders (%) | 21.54% |
| Owned by Institutions (%) | 7.78% |
| Float | 1.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,679.35 |
| Forward PS | n/a |
| PB Ratio | 3.84 |
| P/TBV Ratio | 3.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,561.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63
| Current Ratio | 1.63 |
| Quick Ratio | 0.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -350.30% and return on invested capital (ROIC) is -220.85%.
| Return on Equity (ROE) | -350.30% |
| Return on Assets (ROA) | -129.43% |
| Return on Invested Capital (ROIC) | -220.85% |
| Return on Capital Employed (ROCE) | -321.82% |
| Weighted Average Cost of Capital (WACC) | -1.58% |
| Revenue Per Employee | $3,000 |
| Profits Per Employee | -$4.22M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.88% in the last 52 weeks. The beta is -1.06, so TCRT's price volatility has been lower than the market average.
| Beta (5Y) | -1.06 |
| 52-Week Price Change | -53.88% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 2.90 |
| Relative Strength Index (RSI) | 37.02 |
| Average Volume (20 Days) | 15,728 |
Short Selling Information
The latest short interest is 11,607, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 11,607 |
| Short Previous Month | 13,903 |
| Short % of Shares Out | 0.48% |
| Short % of Float | 0.61% |
| Short Ratio (days to cover) | 0.94 |
Income Statement
In the last 12 months, TCRT had revenue of $3,000 and -$4.22 million in losses. Loss per share was -$2.07.
| Revenue | 3,000 |
| Gross Profit | -1.44M |
| Operating Income | -4.14M |
| Pretax Income | -4.11M |
| Net Income | -4.22M |
| EBITDA | -4.13M |
| EBIT | -4.14M |
| Loss Per Share | -$2.07 |
Full Income StatementBalance Sheet
The company has $354,000 in cash and n/a in debt, giving a net cash position of $354,000 or $0.15 per share.
| Cash & Cash Equivalents | 354,000 |
| Total Debt | n/a |
| Net Cash | 354,000 |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 1.29M |
| Book Value Per Share | 0.54 |
| Working Capital | 375,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.13 million and capital expenditures -$98,000, giving a free cash flow of -$3.23 million.
| Operating Cash Flow | -3.13M |
| Capital Expenditures | -98,000 |
| Depreciation & Amortization | 14,500 |
| Net Borrowing | n/a |
| Free Cash Flow | -3.23M |
| FCF Per Share | -$1.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -138,166.67% |
| Pretax Margin | -136,966.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |